Cerebrovascular risk factors and clinical classification of strokes

Seminars in Vascular Medicine

Volumn 4, Issue 3, 2004, Pages 287-303

  Pinto, Antonio ^a,b   Tuttolomondo, Antonino ^b   Di Raimondo, Domenico ^b   Fernandez, Paola ^b   Licata, Giuseppe ^b  

^a Istituto di Clinica Medica   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cerebrovascular risk; Stroke; TOAST classification

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; INTERLEUKIN 1BETA; PLASMA PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DIABETES MELLITUS; DISEASE CLASSIFICATION; EMBOLISM; GLUCOSE METABOLISM; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPERURICEMIA; INFLAMMATION; MICROALBUMINURIA; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; PROTEINURIA; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STROKE;

ALBUMINURIA; ATRIAL FIBRILLATION; CAROTID STENOSIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL; DIABETES COMPLICATIONS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; HYPERURICEMIA; INFLAMMATION; OBESITY; PROTEINURIA; RISK FACTORS; SMOKING;

EID: 11844282778     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-861497     Document Type: Review

References (73)

1. Gaddi A, Cicero A, Poli A, Nascetti S, Inzitari D, on behalf of the Italian Group for the Study of Dysmetabolic Diseases and Atherosclerosis. Cerebrovascular disease in Italy and Europe: it is necessary to prevent a pandemic. J Cardiovasc Risk 2002;9:143-145
2. Cupples A, D'Agostino RR. Some risk factors related to the incidence of cardiovascular disease and death using pooled repeated biennial measurements: the Framingham Study. 30 year follow-up. In: Kannel W, Wolf P, Garrison R, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. National Institutes of Health publication 87-2703 Bethesda, MD: National Heart, Lung, and Blood Institute; 1987
3. Mittelmark MB, Psaty BM, Rautaharju PM, Fried LP, Borhani NO. Prevalence of cardiovascular diseases among older adults. The Cardiovascular Health Study. Am J Epidemiol 1993;137:311-317
4. Whisnant JP, Wiebers DO, O'Fallon WM, Sicks JD, Frye RL. A population-based model of risk factors for ischemic stroke: Rochester, Minnesota. Neurology 1996;47:1420-1428
5. Jamrozik K, Dobson A, Hobbs M, et al. Monitoring the Incidence of Cardiovascular Disease in Australia. Canberra: Australian Institute of Health and Welfare; 2001
6. Davis BR, Vogt T, Frost PH, Burlando A, Cohen J. Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Stroke 1998;29:1333-1340
7. Imam I. Stroke: a review with an African perspective. Ann Trop Med Parasitol 2002;96:435-445
8. Whittley CY, Gorelick PB, Raman R, Harris J, Richardson D. Are there differences in risk factor profiles and frequency of CT/MRI-based infarcts among African American stroke patients with and without hypertension? A report from the African American Antiplatelet Stroke Prevention Study (AAASPS). J Natl Med Assoc 2003;95:423-432
9. Tiengo A, Del Prato S. Plurimetabolic syndrome: association of diabetes, dyslipidemia, and arterial hypertension [in Italian]. Cardiologia 1995;40(12 Suppl 1):237-243
10. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774
11. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838
12. Tuomilheto J, Rastenyte D, Birkenhanger W, et al. for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999;340:677-684
13. Hannsson L, Zanchetti A, Carruthers SG, et al. for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762
14. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153
15. PROGRESS collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6.105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041
16. Dahlof B, Devereux B, Kjeldsen SE, et al for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
17. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000;101:1653-1659
18. Burchfield CM, Curb JD, Rodriguez BL, Abbott RD, Chiu D, Yano K. Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke 1994;25:951-957
19. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS. Stroke in patients with diabetes. The Copenhagen Stroke Study. Stroke 1994;25:1977-1984
20. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994;25:1157-1164
21. Tuomiletho J, Rastenitè D, Jousilhati P, Sarti C, Vartiainen E. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke 1996;27:210-215
22. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996;27:63-68
23. Adler AI, Stratton IM, Neil HAW, Yudkin JS. on behalf of the UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419
24. Gillett M, Davis WA, Jackson D, Bruce DG, Davis TM. for the Fremantle Diabetes Study. Prospective evaluation of carotid bruit as a predictor of first stroke in type 2 diabetes: the Fremantle Diabetes Study. Stroke 2003;34:2145-2151
25. Licata G, Tuttolomondo A, Sinagra D, Pinto A. Diabetes mellitus and stroke [in Italian]. Ital Heart J Suppl 2002;3:471-477
26. Licata G, Tuttolomondo A, Corrao S, Pinto A. Diabete ed ictus. Ann Med Intern 2003:64-89
27. Licata G, Tuttolomondo A, Pinto A. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke. Data from the European BIOMED Stroke Project (letter). Stroke 2004;35:e61
28. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI. Insulin resistance and risk for stroke. Neurology 2002;59:809-815
29. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men. The 22-year follow-up results of the Helsinki Policemen Study. Stroke 1998;29:1860-1866
30. Beamer NB, Coull BM, Clark WM, Wynn M. Microalbuminuria in ischemic stroke. Arch Neurol 1999;56:699-702
31. Guerrero-Romero F, Rodriguez-Moran M. Proteinuria is an independent risk factor for ischemic stroke in non-insulin-dependent diabetes mellitus. Stroke 1999;30:1787-1791
32. Konishi M, Iso H, Komachi Y, Iida M, Shimamaoto T. Association of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries. The Akita Pathology Study. Stroke 1993;24:954-964
33. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. for the MRFIT Research Group. Serum cholesterol levels and six-year mortality from stroke in 350.977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989;320:904-910
34. Horenstein RB, Smith DE, Mosca L for the Women Poling Project Investigators. Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke 2002;33:1863-1868
35. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
36. Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. Circulation 1999;99:216-223
37. The Long-tern Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357
38. Sheperd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307
39. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622
40. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5693 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;361:2005-2016
41. Sever PS, Dhalof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158
42. Rexrode KM, Hennekens CH, Willet WC, et al. A prospective study of body mass index, weight change and risk of stroke in women. JAMA 1997;277:1539-1545
43. Folsom AR, Rasmussen ML, Chambless LE, et al. for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. Diabetes Care 1999;22:1077-1083
44. Kurth T, Gaziano JM, Berger K, et al. Body mass index and the risk of stroke in men. Arch Intern Med 2002;162:2557-2562
45. Letho S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998;29:635-639
46. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003;34:1951-1956
47. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo controlled, randomised trial of warfarin and aspirin prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989;1:175-179
48. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998;279:1273-1277
49. Singer DE, Hughes RA, Gress DR, et al. The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study. Am Heart J 1992;124:1567-1573
50. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-355
51. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five controlled randomized trials. Arch Intern Med 1994;154:1449-1457
52. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation. Relationship to stroke risk factors. Circulation 2002;106:1962-1967
53. Kaarisalo MM, Immonen-Raiha P, Marttila RJ, et al. Atrial fibrillation in older stroke patients: association with recurrence and mortality after first ischemic stroke. J Am Geriatr Soc 1997;45:1297-1301
54. Penado S, Cano M, Acha O, Hernandez JL, Riancho JA. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med 2003;114:206-210
55. Aronow WS, Ahn CA, Gutsein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J Am Geriatr Soc 1996;44:521-523
56. Di Tullio MR, Zwas DR, Sacco RL, et al. Left ventricular mass and geometry and the risk of ischemic stroke. Stroke 2003;34:2380-2384
57. Benavente O, Moher D, Pham B. Carotid endarterectomy for asymptomatic carotid stenosis: a meta-analysis. BMJ 1998;317:1477-1480
58. Inzitari D, Eliasziw M, Gates P, et al. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. N Engl J Med 2000;342:1693-1700
59. Nicolaides A, Sabetai M, Kakkos SK, et al. The Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study. Aims and results of quality control. Int Angiol 2003;22:263-272
60. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988;259:1025-1029
61. Haheim LL, Holme I, Hjermann I, Leren P. Smoking habits and risk of fatal stroke: 18 years follow-up of the Oslo Study. J Epidemiol Community Health 1996;50:621-624
62. Yamagishi K, Iso H, Kitamura A, et al. Smoking raises the risk of total and ischemic strokes in hypertensive men. Hypertens Res 2003;26:209-217
63. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risk of stroke in women. JAMA 1993;269:232-236
64. Shaper A, Wannamethee S, Walker M. Pipe and cigar smoking and major cardiovascular events, cancer incidence and all causes mortality in middle-aged British men. Int J Epidemiol 2003;32:802-808
65. Jacobs DR Jr, Adachi H, Mulder I, et al. Cigarette smoking and mortality risk: twenty-five-year follow-up of the Seven Countries Study. Arch Intern Med 1999;159:733-740
66. Arenillas JF, Alvarez-Sabin J, Molina CA, et al. C-reactive protein predicts further ischemic events in first-episode of transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 2003;34:2463-2468
67. Sanchez-Moreno C, Dashe JF, Scott T, Thaler D, Folstein MF, Martin A. Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. Stroke 2004;35:163-168
68. Lind P, Engstrom G, Stavenow L, Janzon L, et al. Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 2004;24:577-582
69. Engstrom G, Stavenow L, Hedblad B, et al. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population based study. Diabetes 2003;52:442-447
70. Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation 2002;105:2632-2637
71. Peress NS, Kane WC, Aronson SM. Central nervous system findings in a tenth decade autopsy population. Prog Brain Res 1973;40:473-483
72. Kolominsky-Rabas P, Weber M, Gefeller O, Neundoerfer B, Heuschmann U. Epidemiology of ischemic stroke subtyped according to TOAST criteria. Incidence, recurrence, and long term survival in ischemic stroke subtypes: a population-based study. Stroke 2001;32:2735-2740
73. Megherbi SE, Milan C, Minier D, et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke. Data from the European BIOMED Study of Stroke Care Group. Stroke 2003;34:688-694